Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2012 Earnings Results

Alnylam Pharmaceuticals Beats on EPS, Stock Down 4.28%

Alnylam Pharmaceuticals reported a narrower-than-expected loss per share, which was a positive surprise for investors. However, the stock fell by 4.28% following the earnings report, likely due to the lack of revenue details and forward guidance. Investors may be concerned about the company's future performance without clear guidance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.25	N/A	+31.13%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management expressed cautious optimism about future developments. They acknowledged current market challenges but emphasized their commitment to innovation.

Management highlighted ongoing progress in their pipeline.

They noted challenges in the market but remain focused on long-term goals.

Alnylam Pharmaceuticals Beats on EPS, Stock Down 4.28%

Key numbers

Management commentary

Alnylam Pharmaceuticals, Inc.

More earnings this week

Alnylam Pharmaceuticals Beats on EPS, Stock Down 4.28%

Key numbers

Management commentary